Korean Biotech Startup Targeting Alzheimer’s Treatment Raises $42 Million Round

forbes.com/sites/zinnialee/2025/07/16/korean-biotech-startup-targeting-alzheimers-treatment-raises-42-million-round

Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into treatments for Alzheimer’s disease and expand into immune diseases.
The Series B was led by Korean venture capital firm DSC Investment, whose portfolio includes billionaire Chung Yong-ji’s…

This story appeared on forbes.com, 2025-07-16 13:00:04.
The Entire Business World on a Single Page. Free to Use →